Edge Therapeutics Company Profile (NASDAQ:EDGE)

About Edge Therapeutics (NASDAQ:EDGE)

Edge Therapeutics logoEdge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company's initial product candidates target rare, acute, life-threatening neurological and other conditions. The Company's product candidates utilize its programmable, biodegradable polymer-based development platform (the Precisa Platform), a delivery mechanism that seeks to enable targeted and sustained drug exposure and avoid the dose-limiting side effects associated with the current standards of care. The Company's product candidates include EG-1962 and EG-1964. EG-1962 is a polymer-based microsphere containing nimodipine suspended in a diluent of sodium hyaluronate was developed using its Precisa development platform to improve patient outcomes following aneurysmal subarachnoid hemorrhage (aSAH).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:EDGE
  • CUSIP: N/A
  • Web: www.edgetherapeutics.com
Capitalization:
  • Market Cap: $305.03 million
  • Outstanding Shares: 30,811,000
Average Prices:
  • 50 Day Moving Avg: $9.75
  • 200 Day Moving Avg: $10.41
  • 52 Week Range: $7.30 - $13.50
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.63
  • P/E Growth: -0.06
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $2.71 per share
  • Price / Book: 3.65
Profitability:
  • EBIDTA: ($41,840,000.00)
  • Return on Equity: -33.77%
  • Return on Assets: -30.43%
Debt:
  • Debt-to-Equity Ratio: 0.15%
  • Current Ratio: 26.62%
  • Quick Ratio: 26.62%
Misc:
  • Average Volume: 67,369 shs.
  • Beta: 2.83
  • Short Ratio: 11.6
 

Frequently Asked Questions for Edge Therapeutics (NASDAQ:EDGE)

What is Edge Therapeutics' stock symbol?

Edge Therapeutics trades on the NASDAQ under the ticker symbol "EDGE."

How were Edge Therapeutics' earnings last quarter?

Edge Therapeutics Inc (NASDAQ:EDGE) issued its quarterly earnings data on Wednesday, May, 3rd. The company reported ($0.42) EPS for the quarter, beating the Zacks' consensus estimate of ($0.42) by $0.00. View Edge Therapeutics' Earnings History.

When will Edge Therapeutics make its next earnings announcement?

Edge Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for Edge Therapeutics.

Where is Edge Therapeutics' stock going? Where will Edge Therapeutics' stock price be in 2017?

2 equities research analysts have issued 1-year price objectives for Edge Therapeutics' stock. Their forecasts range from $21.00 to $30.00. On average, they expect Edge Therapeutics' stock price to reach $25.50 in the next year. View Analyst Ratings for Edge Therapeutics.

Are investors shorting Edge Therapeutics?

Edge Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totalling 732,952 shares, an increase of 6.4% from the March 15th total of 688,740 shares. Based on an average daily volume of 80,705 shares, the short-interest ratio is currently 9.1 days.

Who are some of Edge Therapeutics' key competitors?

Who owns Edge Therapeutics stock?

Edge Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Janus Capital Management LLC (6.87%), VHCP Management II LLC (6.66%), SATTER MUNEER A (5.80%), Eagle Asset Management Inc. (3.10%), Vanguard Group Inc. (2.41%) and Geode Capital Management LLC (0.60%). Company insiders that own Edge Therapeutics stock include Andrew J Einhorn, Brian A Leuthner, James Healy, James J Loughlin and W Bradford Middlekauff. View Institutional Ownership Trends for Edge Therapeutics.

Who sold Edge Therapeutics stock? Who is selling Edge Therapeutics stock?

Edge Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Janus Capital Management LLC, Morgan Stanley, JPMorgan Chase & Co., TIAA CREF Investment Management LLC and Mark Sheptoff Financial Planning LLC. View Insider Buying and Selling for Edge Therapeutics.

Who bought Edge Therapeutics stock? Who is buying Edge Therapeutics stock?

Edge Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Regentatlantic Capital LLC, Eagle Asset Management Inc., Renaissance Technologies LLC, TFS Capital LLC, Vanguard Group Inc., Spark Investment Management LLC, Trexquant Investment LP and Geode Capital Management LLC. Company insiders that have bought Edge Therapeutics stock in the last two years include Andrew J Einhorn, James Healy, James J Loughlin and W Bradford Middlekauff. View Insider Buying and Selling for Edge Therapeutics.

How do I buy Edge Therapeutics stock?

Shares of Edge Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Edge Therapeutics stock cost?

One share of Edge Therapeutics stock can currently be purchased for approximately $9.90.

Analyst Ratings

Consensus Ratings for Edge Therapeutics (NASDAQ:EDGE) (?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $25.50 (157.58% upside)

Analysts' Ratings History for Edge Therapeutics (NASDAQ:EDGE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/3/2017Leerink SwannReiterated RatingOutperform -> Outperform$21.00N/AView Rating Details
3/3/2017GuggenheimReiterated RatingBuy -> In-Line$30.00N/AView Rating Details
5/9/2016Credit Suisse Group AGLower Price TargetOutperform$19.00 -> $18.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$34.00 -> $18.00N/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Edge Therapeutics (NASDAQ:EDGE)
Earnings by Quarter for Edge Therapeutics (NASDAQ:EDGE)
Earnings History by Quarter for Edge Therapeutics (NASDAQ:EDGE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2017        
5/3/2017Q1 2017($0.42)($0.42)ViewListenView Earnings Details
3/2/2017Q4 2016($0.42)($0.33)ViewListenView Earnings Details
8/3/2016Q2($0.38)($0.33)ViewListenView Earnings Details
5/3/2016Q1 2016($0.34)($0.32)ViewListenView Earnings Details
3/8/2016Q4($0.32)($0.30)ViewListenView Earnings Details
11/6/2015Q315($0.23)($7.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Edge Therapeutics (NASDAQ:EDGE)
2017 EPS Consensus Estimate: ($1.89)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.42)($0.42)($0.42)
Q2 20171($0.45)($0.45)($0.45)
Q3 20171($0.48)($0.48)($0.48)
Q4 20171($0.54)($0.54)($0.54)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Edge Therapeutics (NASDAQ:EDGE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Edge Therapeutics (NASDAQ:EDGE)
Insider Ownership Percentage: 44.29%
Institutional Ownership Percentage: 49.25%
Insider Trades by Quarter for Edge Therapeutics (NASDAQ:EDGE)
Institutional Ownership by Quarter for Edge Therapeutics (NASDAQ:EDGE)
Insider Trades by Quarter for Edge Therapeutics (NASDAQ:EDGE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/6/2017James J LoughlinDirectorBuy3,000$9.24$27,720.00View SEC Filing  
2/7/2017Brian A LeuthnerInsiderSell1,500$9.52$14,280.00View SEC Filing  
2/6/2017Brian A LeuthnerInsiderSell3,000$9.61$28,830.00View SEC Filing  
2/2/2017Brian A LeuthnerInsiderSell3,000$9.50$28,500.00View SEC Filing  
12/1/2016Brian A LeuthnerInsiderSell7,500$11.60$87,000.00View SEC Filing  
10/3/2016Brian A LeuthnerInsiderSell7,500$10.25$76,875.00View SEC Filing  
8/8/2016W Bradford MiddlekauffVPBuy10,000$9.48$94,800.00View SEC Filing  
8/1/2016Brian A LeuthnerInsiderSell7,500$9.54$71,550.00View SEC Filing  
3/11/2016James HealyDirectorBuy541,343$7.30$3,951,803.90View SEC Filing  
10/6/2015Andrew J. EinhornCFOBuy45,000$11.00$495,000.00View SEC Filing  
10/6/2015James HealyDirectorBuy450,000$11.00$4,950,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Edge Therapeutics (NASDAQ:EDGE)
Latest Headlines for Edge Therapeutics (NASDAQ:EDGE)
Source:
DateHeadline
nasdaq.com logoEuropean ADRs Edge Higher as Telecommunication Stocks Advance
www.nasdaq.com - May 12 at 5:22 PM
americanbankingnews.com logoEdge Therapeutics Inc (EDGE) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 6 at 12:40 AM
americanbankingnews.com logoEdge Therapeutics Inc (EDGE) Posts Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - May 6 at 12:17 AM
americanbankingnews.com logoEdge Therapeutics Inc (EDGE) Releases Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - May 5 at 11:52 PM
americanbankingnews.com logoEdge Therapeutics Inc (EDGE) Releases Quarterly Earnings Results
www.americanbankingnews.com - May 5 at 2:30 PM
americanbankingnews.com logoLeerink Swann Weighs in on Edge Therapeutics Inc's Q2 2017 Earnings (EDGE)
www.americanbankingnews.com - May 5 at 9:29 AM
finance.yahoo.com logoEdited Transcript of EDGE earnings conference call or presentation 3-May-17 12:30pm GMT
finance.yahoo.com - May 4 at 11:43 AM
americanbankingnews.com logoEdge Therapeutics (EDGE) Receiving Somewhat Positive Press Coverage, Report Finds
www.americanbankingnews.com - May 4 at 9:18 AM
reuters.com logoBRIEF-Edge Therapeutics Qtrly loss per share $0.42
www.reuters.com - May 3 at 4:47 PM
finance.yahoo.com logoEdge Therapeutics Reports First Quarter 2017 Financial Results and Continued Operational Progress
finance.yahoo.com - May 3 at 10:24 AM
finance.yahoo.com logoInvestor Network: Edge Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - May 3 at 10:24 AM
marketbeat.com logoEdge Therapeutics reports 1Q loss
marketbeat.com - May 3 at 6:42 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Edge Therapeutics Inc (EDGE) to Announce -$0.42 EPS
www.americanbankingnews.com - May 2 at 8:00 PM
americanbankingnews.com logoEdge Therapeutics (EDGE) Earns News Impact Score of 0.17
www.americanbankingnews.com - April 30 at 1:53 PM
americanbankingnews.com logoEdge Therapeutics (EDGE) Receiving Positive Media Coverage, Study Shows
www.americanbankingnews.com - April 27 at 10:56 PM
americanbankingnews.com logoShort Interest in Edge Therapeutics Inc (EDGE) Increases By 6.4%
www.americanbankingnews.com - April 26 at 9:59 AM
americanbankingnews.com logoEdge Therapeutics (EDGE) Earning Somewhat Critical Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 20 at 5:00 PM
streetinsider.com logoEdge Therapeutics (EDGE) Enters Agreement for $18M Registered Direct Offering of Common Stock
www.streetinsider.com - April 20 at 9:22 AM
reuters.com logoBRIEF-Edge Therapeutics announces $18 mln registered direct offering of common stock
www.reuters.com - April 20 at 9:22 AM
nasdaq.com logoEdge Therapeutics Announces $18 Million Registered Direct Offering of Common Stock
www.nasdaq.com - April 19 at 12:21 PM
americanbankingnews.com logoEdge Therapeutics (EDGE) Earning Somewhat Negative Media Coverage, Report Shows
www.americanbankingnews.com - April 15 at 9:45 AM
americanbankingnews.com logo Analysts Anticipate Edge Therapeutics Inc (EDGE) to Announce -$0.42 EPS
www.americanbankingnews.com - April 11 at 2:13 PM
americanbankingnews.com logo Edge Therapeutics Inc (EDGE) Given $21.00 Consensus Target Price by Brokerages
www.americanbankingnews.com - April 6 at 8:04 AM
globenewswire.com logoEdge Therapeutics to Present at Needham & Company's 16th Annual Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - March 30 at 5:20 PM
finance.yahoo.com logoEdge Therapeutics to Present at Needham & Company’s 16th Annual Healthcare Conference
finance.yahoo.com - March 29 at 11:37 AM
nasdaq.com logoEuropean ADRs Edge Higher as Banks See Mixed Fortunes
www.nasdaq.com - March 17 at 10:13 PM
biz.yahoo.com logoEDGE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statem
biz.yahoo.com - March 15 at 8:20 PM
nasdaq.com logoEdge Therapeutics Announces First Patient Randomized in Study of ... - Nasdaq
www.nasdaq.com - March 14 at 12:56 PM
reuters.com logoBRIEF-Edge Therapeutics says Albert Marchio II became CFO on an interim basis
www.reuters.com - March 13 at 12:00 PM
streetinsider.com logoForm 8-K Edge Therapeutics, Inc. For: Mar 10
www.streetinsider.com - March 13 at 12:00 PM
biz.yahoo.com logoEDGE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - March 13 at 12:00 PM
finance.yahoo.com logoEdge Therapeutics Announces First Patient Randomized in Study of Intracisternal Administration of EG-1962 in Adults with Aneurysmal Subarachnoid Hemorrhage
finance.yahoo.com - March 13 at 12:00 PM
finance.yahoo.com logoEDGE THERAPEUTICS, INC. Financials
finance.yahoo.com - March 8 at 5:42 PM
us.rd.yahoo.com logoEdited Transcript of EDGE earnings conference call or presentation 2-Mar-17 1:30pm GMT
us.rd.yahoo.com - March 3 at 4:57 PM
finance.yahoo.com logoEdge Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
finance.yahoo.com - March 2 at 5:08 PM
biz.yahoo.com logoEDGE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
biz.yahoo.com - March 2 at 5:08 PM
biz.yahoo.com logoQ4 2016 Edge Therapeutics Inc Earnings Release - Time Not Supplied
biz.yahoo.com - March 2 at 5:08 PM
biz.yahoo.com logoEdge Therapeutics Inc Earnings Call scheduled for 8:30 am ET today
biz.yahoo.com - March 2 at 5:08 PM
feeds.benzinga.com logoEdge Therapeutics Appoints Alyssa Wyant as Senior Vice President, Regulatory Affairs and Makes Inducement Grant under NASDAQ Rule 5635(c)(4)
feeds.benzinga.com - February 21 at 7:51 AM
finance.yahoo.com logoEdge Therapeutics’ EG-1962 Data To Be Presented at International Stroke Conference 2017
finance.yahoo.com - February 17 at 6:22 PM
finance.yahoo.com logoEdge Therapeutics to Present at Investor Conferences in February
finance.yahoo.com - February 8 at 5:24 PM
businesswire.com logoVividion Therapeutics, Inc., Launches With $50 Million Series A Financing
www.businesswire.com - February 2 at 10:23 PM
streetinsider.com logoForm 4 Edge Therapeutics, Inc. For: Jan 23 Filed by: Macdonald R. Loch - StreetInsider.com
www.streetinsider.com - January 26 at 6:11 PM
globenewswire.com logoIntellia Therapeutics Joins Genomics England’s Industry Consortium
www.globenewswire.com - January 11 at 5:26 PM
prnewswire.com logoGenVec to Present at Phacilitate Cell & Gene Therapy World 2017
www.prnewswire.com - January 11 at 5:26 PM
globenewswire.com logoEdge Therapeutics Announces Publication of Phase 1/2 Data on EG ... - GlobeNewswire (press release)
globenewswire.com - December 9 at 5:09 PM
finance.yahoo.com logo9:18 am Edge Therapeutics announces publication of results from its Phase 1/2 clinical study of EG-1962 online at Stroke
finance.yahoo.com - December 9 at 5:09 PM
finance.yahoo.com logoEdge Therapeutics Announces Publication of Phase 1/2 Data on EG-1962 for the Treatment of Aneurysmal Subarachnoid Hemorrhage in Peer-Reviewed Medical Journal, Stroke
finance.yahoo.com - December 9 at 5:09 PM
businesswire.com logoEvotec and Forge Therapeutics Form Strategic 'Superbug' Alliance
www.businesswire.com - December 9 at 8:03 AM
nasdaq.com logoEuropean ADRs Edge Lower as Manufacturers Post Mixed Fortunes
www.nasdaq.com - December 8 at 10:34 PM

Social

Chart

Edge Therapeutics (EDGE) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff